Company news

Palatin Technologies, Inc. news in 2025

Palatin Technologies, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option

November 12, 2025

Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update

May 14, 2025

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025

May 9, 2025

Palatin Technologies Announces Closing of Reduced Public Offering

May 8, 2025

Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025

May 8, 2025

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice

May 7, 2025

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice

May 7, 2025

Palatin Technologies Announces Pricing of up to $23 Million Public Offering

May 7, 2025

Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy

May 5, 2025

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

April 29, 2025

Calls in 2025

Decks in 2025